24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension

Hepşen, İbrahim F.; Özkaya, Enis

doi:10.1038/sj.eye.6702243

Cited by 17 publications

(11 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In earlier clinical studies comparing latanoprost to travoprost, some investigators concluded that the effectiveness of both agents to lower the IOP was comparable [8,9,11,13], while others concluded that travoprost was more effective than latanoprost [4-6, 10, 12]. However, there [26].…”

Section: Discussionmentioning

confidence: 99%

“…Of these, travoprost was originally developed with benzalkonium chloride (BAK) as a preservative; however, only 0.004% travoprost ophthalmic solution without BAK (Travatan Z, Alcon Laboratories Inc, Fort Worth, TX, USA) is now available in Japan. It has been reported that travoprost without BAK solution has a similar IOP-lowering effect and safety to that of travoprost with BAK [3], and its effectiveness is equal or greater than that of latanoprost [4][5][6][7][8][9][10][11][12][13]. Both drugs reduce the IOP by approximately 20 to 40% of the baseline IOP [4][5][6][8][9][10][11][12][13].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Randomized crossover study of latanoprost and travoprost in eyes with open-angle glaucoma

Sawada

Yamamoto

Takatsuka

2011

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Randomized crossover study of latanoprost and travoprost in eyes with open-angle glaucoma

Sawada

Yamamoto

Takatsuka

2011

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Figure 1 presents details of the exclusion criteria at the various stages during the study selection process. Five trials had more than 2 intervention arms, 28 [28][29][30][31][32][39][40][41] We did not pool the data from one trial, reported as an abstract, as we were unable to determine the group sizes. 42 Table 1 and 2 report the study characteristics and quality (see Tables 1 and 2).…”

Section: Resultsmentioning

confidence: 99%

Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis

Eyawo

Nachega

Lefèbvre

et al. 2009

OPTH

View full text Add to dashboard Cite

Background: First-line therapy for primary open-angle glaucoma and ocular hypertension generally involves prostaglandin analogue therapy. The relative efficacy of differing prostaglandin therapy is disputed. Methods: A meta-analysis was conducted of head-to-head randomized trials of prostaglandin therapies. We included randomized trials assessing head-to-head evaluations of prostaglandin analogues travoprost, latanoprost and bimatoprost in patients with predominantly primary open-angle glaucoma or ocular hypertension. Findings were interpreted in light of equivalence margins. Results: Our search identified 16 eligible trials, of which 15 were included in the meta-analysis. Trials were, in general, poorly reported. We pooled 9 trials assessing IOP-lowering effects of travoprost vs latanoprost (total n = 1098, weighted mean difference [WMD], -0.24 mmHg, 95% CI, -0.87 to 0.38, P = 0.45, I 2 = 56%, 95% CI, 0 to 0.77, heterogeneity P = 0.01). Eight trials assessed travoprost vs bimatoprost (total n = 714, WMD, 0.88 mmHg, 95% CI, 0.13 to 1.63, P = 0.02, I 2 = 56%, 95% CI, 0% to 78%, heterogeneity P = 0.02). And 8 trials assessed latanoprost vs bimatoprost (total n = 943, WMD, 0.73 mmHg, 95% CI, 0.10 to 1.37, P = 0.02, I 2 = 47%, 95% CI, 0% to 74%, heterogeneity P = 0.06). Travoprost was associated with greater incidence of conjunctival hyperemia than latanoprost (RR 5.71, 95% CI, 1.81 to 18.02, P  0.001, I 2 = 97%, 95% CI, 95 to 98, P  0.001). Five trials assessing latanoprost and bimatoprost revealed an elevated risk of conjunctival hyperemia with bimatoprost (RR 1.59, 95% CI, 1.02 to 2.48, P = 0.04, I 2 = 76%, 95% CI, 16 to 88, P = 0.002). Conclusion: Randomized head-to-head evaluations of prostaglandin therapy demonstrate similar efficacy effects, but differing hyperemia effects.

show abstract

“…68 Several meta-analyses [88][89][90][91] have directly compared the clinical efficacy of the three main PGAs, latanoprost, travoprost, and bimatoprost. Two independent meta-analyses, one 88 of 8 63,64,68,78,[85][86][87]92 and the other 89 of 13 trials (including double-blind parallel 57,63,93 or cross-over studies 41,42 and single blind parallel 64,78,85,86,[94][95][96] or cross-over studies) 97 found bimatoprost was superior to latanoprost in lowering morning IOP at all time points, supported by a later posthoc meta-analysis of 2 independent trials with 6 months follow-up. Weighted mean difference (WMD) for %IOP reduction (%IOPR) was 2.59% (P = 0.004) at 1 month to 5.60% (P , 0.001) at 6 months for one meta-analysis 89 and weighted mean (WM) IOP change from baseline ranged from a minimum of 0.50 mmHg (P = 0.05) at 0800 hours to a maximum of 1.17 mmHg (P , 0.001) at 1200 hours in the other meta-analysis 88 favoring bimatoprost over latanoprost.…”

mentioning

confidence: 95%

“…Bimatoprost was superior in IOP lowering to travoprost only during the daytime (0800 and 1200 hours time-points), but latanoprost and travoprost were comparable at all time points (P # 0.82). 88 An industry-sponsored meta-analysis 90 of travoprost vs latanoprost (15 trials, n = 1098), 57,68,85,93,95,96,[98][99][100] travoprost vs bimatoprost (8 trials, n = 714), 57,85,87,93,95,96,101,102 and latanoprost vs bimatoprost (8 trials, n = 943) 57,64,85,86,93,95,96,103 found similar efficacy among the three PGAs. Studies comparing the PGA to other non-PGA glaucoma treatments, nonrandomized, dose-finding or cross-over trials, and short-term evaluations (less than 3 months) were excluded, although a trial evaluating timolol plus travoprost versus timolol alone, 100 was included indicating that the PGA effect has the same relative effect as if it were compared with no treatment.…”

mentioning

confidence: 99%

Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension

Lee

McCluskey

2010

OPTH

View full text Add to dashboard Cite

Prostaglandin analogs (PGA) are powerful topical ocular hypotensive agents available for the treatment of elevated intraocular pressure (IOP). Latanoprost 0.005% and travoprost 0.004% are prodrugs and analogs of prostaglandin F2α. Bimatoprost 0.03% is regarded as a prostamide, and debate continues as to whether it is a prodrug. The free acids of all 3 PGAs reduce IOP by enhancing uveoscleral and trabecular outflow via direct effects on ciliary muscle relaxation and remodeling of extracellular matrix. The vast majority of clinical trials demonstrate IOP-lowering superiority of latanoprost, bimatoprost and travoprost compared with timolol 0.5%, brimonidine 0.2%, or dorzolamide 2% monotherapy. Bimatoprost appears to be more efficacious in IOPlowering compared with latanoprost, with weighted mean difference in IOP reduction documented in one meta-analysis of 2.59% to 5.60% from 1-to 6-months study duration. PGAs reduce IOP further when used as adjunctive therapy. Fixed combinations of latanoprost, bimatoprost or travoprost formulated with timolol 0.5% and administered once daily are superior to monotherapy of its constituent parts. PGA have near absence of systemic side effects, although do have other commonly encountered ocular adverse effects. The adverse effects of PGA, and also those found more frequently with bimatoprost use include ocular hyperemia, eyelash growth, and peri-ocular pigmentary changes. Iris pigmentary change is unique to PGA treatment. Once daily administration and near absence of systemic side effects enhances tolerance and compliance. PGAs are often prescribed as first-line treatment for ocular hypertension and open-angle glaucoma.

show abstract

24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension

Cited by 17 publications

References 20 publications

Randomized crossover study of latanoprost and travoprost in eyes with open-angle glaucoma

Randomized crossover study of latanoprost and travoprost in eyes with open-angle glaucoma

Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis

Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension

Contact Info

Product

Resources

About